Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312424 · ClinicalTrials.gov registry record · Phase 1
Annatto-derived GG for Statin-associated Myopathy
A Phase 1 study of Myopathy; Primary, sponsored by Texas Tech University Health Sciences Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT05312424: Recruiting Phase 1 study of Myopathy; Primary, sponsored by Texas Tech University Health Sciences Center.
NCT05312424 is a Phase 1 study of Myopathy; Primary that is actively recruiting participants, run by Texas Tech University Health Sciences Center. The registered enrollment target is 95 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312424, a Phase 1 study of Myopathy; Primary, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
Primary Outcome
Statin-Associated Muscle Symptom Clinical Index (SAMS-CI) is to assess muscle pain, muscle weakness, tiredness, and cramps.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Low GG
- DIETARY_SUPPLEMENT High GG
Study Locations (1)
Texas
- Texas Tech University Health Sciences Center - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT05312424 shows while recruiting
NCT05312424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% higher).
The record links to 1 condition, with Myopathy; Primary appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05312424 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05312424 about?
NCT05312424 is a clinical study titled "Annatto-derived GG for Statin-associated Myopathy". To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
What is the current status of trial NCT05312424?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2022-07-15. Estimated completion is 2027-12-31.
What conditions does trial NCT05312424 study?
This clinical trial studies the following conditions: Myopathy; Primary.
What interventions are being tested in trial NCT05312424?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Low GG (DIETARY_SUPPLEMENT), High GG (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05312424?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312424 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05312424's enrollment target sits among peer trials
95 611th of 2000 higher than 1,386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI